Skip to content
OpenCapital
Get started

Immuneering Corporation IMRX Q4 2024 Annual earnings

Reported March 20, 2025 · Before market open

Diluted EPS-$0.58Miss by $0.16
EPS estimate-$0.42

Next report

Aug 12, 2026 (in a month)
EPS estimate-$0.26

Versus estimates

Diluted EPS

Q1 2026-$0.21Beat by $0.09Q4 2025-$0.18Beat by $0.13Q3 2025-$0.38Miss by $0.01Q2 2025-$0.40In lineQ1 2025-$0.42Miss by $0.01
Q4 2024-$0.58Miss by $0.16

Ask the moment Immuneering Corporation reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Immuneering Corporation report Q4 2024 earnings?
Immuneering Corporation (IMRX) reported Q4 2024 earnings on March 20, 2025 before market open.
What were Immuneering Corporation's Q4 2024 revenue and EPS?
Immuneering Corporation reported diluted EPS of $-0.58 for Q4 2024.
Did Immuneering Corporation beat estimates in Q4 2024?
EPS missed the consensus estimate of $-0.42 by $0.16.
Where can I find Immuneering Corporation's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001790340-25-000042) directly on SEC EDGAR. The filing index links above go to sec.gov.